Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure
Section snippets
Methods
We retrospectively reviewed a database of all patients who underwent pancreatic resection at the Massachusetts General Hospital between February 1985 and November 2006 and identified 499 patients who underwent resection for pathologically confirmed pancreatic ductal adenocarcinoma.
Patient-, tumor-, and treatment-related variables were evaluated. Patient factors evaluated included age, gender, smoking status, and family history. Treatment factors included the type of operation, adjuvant therapy,
Clinicopathologic factors
Between February 1985 and November 2006, 499 patients underwent complete gross resection of a pathologically confirmed pancreatic ductal adenocarcinoma. The cohort was approximately half female (49%) with a median age at diagnosis of 65 years (range, 31–91). The majority of patients (84%) underwent pancreaticoduodenectomy and had stage IIb disease (60%). One third of the patients 35% (174/499) received chemotherapy and 66% (329/499) received radiotherapy with chemotherapy. Even though receiving
Discussion
Most pancreatic cancers are diagnosed at an advance stage. This, together with the aggressiveness of the disease and the lack of effective systemic therapies, results in low rates of overall survival. Operative resection remains the only chance for long-term survival, despite advances in adjuvant and neoadjuvant therapies. The perioperative morbidity and mortality of pancreatic surgery has decreased to 24% and 2%, respectively, over the last 30 years.6, 7, 8 Despite all of these improvements,
References (25)
- et al.
Pancreatic adenocarcinoma: the actual 5-year survivors
J Gastrointest Surg
(2008) - et al.
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators
J Gastrointest Surg
(2000) - et al.
Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy
J Am Coll Surg
(2012) - et al.
Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression
J Surg Res
(2012) - et al.
Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220
Immunity
(1998) - et al.
Long term survival after pancreatic resection for pancreatic adenocarcinoma
Am J Gastroenterol
(2001) - et al.
Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors
J Am Coll Surg
(2004) - et al.
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy
Tumori
(2005) Pancreatic adenocarcinoma
- Howlader N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975–2009 (vintage 2009 populations)...
Cancer statistics, 2010
CA Cancer J Clin
Improved hospital morbidity, mortality, and survival after the Whipple procedure
Ann Surg
Cited by (182)
EZH2 as a potential therapeutic target for gastrointestinal cancers
2024, Pathology Research and PracticePredicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification
2023, European Journal of Surgical OncologyA dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma
2023, Surgery (United States)Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma
2023, Clinics and Research in Hepatology and GastroenterologyClinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma
2023, Asian Journal of Surgery